Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

SUPERNUS PHARMACEUTICALS, INC. (SUPN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
08/25/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Bethany L. Sensenig Joins Supernus’ Board of Directors"
08/10/2023 8-K/A Quarterly results
Docs: "Supernus Announces Second Quarter 2023 Financial Results"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Supernus Announces Second Quarter 2023 Financial Results"
07/24/2023 8-K Quarterly results
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Supernus Announces First Quarter 2023 Financial Results"
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/03/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Even...
Docs: "Supernus Announces Repayment of Convertible Notes"
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/01/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/28/2023 8-K Quarterly results
Docs: "Supernus Announces Fourth Quarter and Full Year 2022 Financial Results"
02/14/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "ab UBS Bank USA Credit Line Agreement Variable Credit Line Account Number: Fixed Credit Line Account Number: Internal Use Only Credit Line Agreement - Demand Facility THIS CREDIT LINE AGREEMENT is made by and between the party or parties signing as the Borrower on the Application to which this Agreement is attached and UBS Bank USA and, together with the Application, establishes the terms and conditions that will govern the uncommitted demand loan facility made available to the Borrower by the Bank and any letter of credit which may be issued by the Bank in its sole and absolute discretion at the request of the Borrower, whether or not the Borrower is identified therein as the account party. This Agreement becomes effective upon the earlier of the date of notice from the Bank to the Borrow...",
"Supernus Enters Into $150 Million Credit Facility ROCKVILLE, MD, February 14, 2023 – Supernus Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced it entered into a credit line agreement with UBS Bank USA providing the Company an uncommitted demand secured line of credit of up to $150 million, which can be drawn at any time. Any fixed rate borrowing will bear interest at a fixed interest rate, equal to the sum of the UBS Fixed Funding Rate plus the applicable Percentage Spread established in the Credit Line. Any variable rate borrowing will bear interest at a variable interest rate, equal to the sum of the UBS Variable Rate plus the applicable Percentage Spread establishe..."
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 8.1% stake in SUPERNUS PHARMACEUTICALS, INC.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 10.7% stake in Supernus Pharmaceuticals Inc.
02/08/2023 5 NEWHALL CHARLES W III (Director) has filed a Form 5 on SUPERNUS PHARMACEUTICALS, INC.
01/23/2023 SC 13G/A BlackRock Inc. reports a 17.8% stake in SUPERNUS PHARMACEUTICALS INC
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "Supernus Announces Third Quarter 2022 Financial Results"
10/25/2022 8-K Quarterly results
10/11/2022 8-K Other Events  Interactive Data
Docs: "Supernus Provides Regulatory Update on SPN-830"
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
07/26/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/09/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy